STAT+: Akeso says its closely watched drug improved patient survival in a lung cancer trial
Written by
STAT News
Published
0
comments
0
min
Akeso, a Chinese biotech with a drug positioned to rival Merck’s Keytruda, reported that its lung cancer therapy can improve patient survival.